| Literature DB >> 33062142 |
Xing Chang1,2, Tian Zhang3, Wenjin Zhang1, Zhenyu Zhao1, Jiahui Sun1.
Abstract
Oxidative stress (OS) refers to the physiological imbalance between oxidative and antioxidative processes leading to increased oxidation, which then results in the inflammatory infiltration of neutrophils, increased protease secretion, and the production of a large number of oxidative intermediates. Oxidative stress is considered an important factor in the pathogenesis of cardiovascular disease (CVD). At present, active components of Chinese herbal medicines (CHMs) have been widely used for the treatment of CVD, including coronary heart disease and hypertension. Since the discovery of artemisinin for the treatment of malaria by Nobel laureate Youyou Tu, the therapeutic effects of active components of CHM on various diseases have been widely investigated by the medical community. It has been found that various active CHM components can regulate oxidative stress and the circulatory system, including ginsenoside, astragaloside, and resveratrol. This paper reviews advances in the use of active CHM components that modulate oxidative stress, suggesting potential drugs for the treatment of various CVDs.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33062142 PMCID: PMC7537704 DOI: 10.1155/2020/5430407
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1The factors that cause cardiovascular disease are complex, including NADPH, NOX, eNOS, NO, and ROS. ROS is the most obviously biological markers of oxidative stress. The increase in oxidative stress directly causes lipid peroxidation, protein and enzyme denaturation, nucleic acid DNA damage, and other mechanisms of the myocardial cell membrane or cardiovascular epithelial cells. These are also important pathways for the action of antioxidant drugs.
Detailed information on bioactive ingredients targeting oxidative stress.
| No. | Active ingredients | Natural drug | Mechanism of action | Treatment disease |
|---|---|---|---|---|
| 1. | Ginsenoside Rb1 |
| (1) Inhibits the expression of proapoptotic genes | (1) Coronary heart disease |
| 2. | Ginsenoside Rg1 |
| (1) Inhibition of | (1) Coronary heart disease |
| 3. | Ginsenoside Rg2 |
| (1) Inhibition of | (1) Coronary heart disease |
| 4. | Delphinidin-3-glucoside | Anthocyanidin | (1) Inhibits the expression of | (1) Coronary heart disease |
| 4. | Total flavonoids of matsuba | Matsuba | (1) Reduce O2 and H2O2 | (1) Coronary heart disease |
| 5. | Orientin |
| (1) Reduces ROS | (1) Coronary heart disease |
| 6. | Hawthorn leaf flavonoids | Genus | (1) Inhibit the formation of LPO | (1) Coronary heart disease |
| 7. | Anemarrhenoside |
| (1) Promoting the production of | Ischemia-reperfusion |
| 8. | Hesperidin | Citrus fruits | (1) Regulating | Ischemia-reperfusion |
| 9. | Resveratrol | Peanuts, red wine, mulberries, etc. | (1) Inhibits the formation of oxygen free radicals | (1) Hypertension |
| 10. | Tea polyphenols | Tea | (1) Increase the activity of | (1) Hypertension |
| 11. | Saponins of |
| (1) Inhibit the formation of LPO and MDA | Hypertension |
| 12. | Berberine |
| Regulates the | Hypertension |
| 13. | Allicin |
| (1) Scavenging free radicals | Hypertension |
| 14. | Curcumin | Rhizome of a turmeric plant | (1) Reducing the formation of peroxides | Hypertension |
| 15. | Astragaloside IV |
| (1) Increases the activity of | (1) Heart failure |
| 16. | Tetramethylpyrazine |
| (1) Increased the expression level of | (1) Heart failure |
| 17. | Gastrodin |
| (1) Inhibits the formation of LPO and oxygen free radicals | Heart failure |
| 18. | Safflower |
| (1) Inducing autophagy | Heart failure |
| 19. | Ferulic acid |
| (1) Inhibition of | Heart failure |
| 20. | Paeonol |
| (1) Increases the activity of | (1) Arrhythmia |
| 21. | Matrine |
| Increases the activity of antioxidant enzyme | Arrhythmia |
| 22. | Astragalus polysaccharide |
| (1) Increases the activity of | (1) Coronary heart disease |
| 23. | Quercetin |
| (1) Inhibits the expression of aldose reductase | (1) Acute myocardial infarction |
| 24. | Tanshinone II-A |
| (1) Upregulation of | (1) Coronary heart disease |
| 25. | Gypenoside |
| (1) Increases the activity of | Acute myocardial infarction |
| 26. | Soybean isoflavone |
| (1) Increases the activity of | (1) Acute myocardial infarction |
| 27. | Hydroxy safflower yellow |
| (1) Activating the | Acute myocardial infarction |
ROS: reactive oxygen species; ap-JNK: C-Jun N-terminal kinase- (JNK-) c-Jun/activated protein (AP); p-ERK: protein kinase R- (PKR-) like endoplasmic reticulum kinase; CK: creatine kinase; LDH: lactate dehydrogenase; LPO: lipid peroxidation; SOD: superoxide dismutase; CAT: catalase; MDA: malondialdehyde; GSH-Px: glutathione peroxidase; eNOS: endothelial nitric oxide synthase; NADPH: nicotinamide adenine dinucleotide phosphate; NOX2: NADPH oxidase 2; NOX4: NADPH oxidase 4; AMPK: adenosine 5′-monophosphate- (AMP-) activated protein kinase; SIRT1: sirtuin1; PI3K: phosphatidylinositol 3-kinase; Akt: serine/threonine kinase Akt; mTOR: mammalian target of rapamycin; Nrf2: nuclear factor erythroid 2-related factor 2; ARE: antioxidant response element; HO-1: heme oxygenase 1; TGF-beta1: transforming growth factor beta 1; NQO1: NAD(P)H quinone dehydrogenase 1.